Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

af Campone, M, Levy, V, Bourbouloux, E, Berton Rigaud, D, Bootle, D, Dutreix, C, Zoellner, U, Shand, N, Calvo, F, Raymond, E
Udgivet 2009

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

af Loussouarn, D, Campion, L, Sagan, C, Frenel, J-S, Dravet, F, Classe, J-M, Pioud-Martigny, R, Berton-Rigaud, D, Bourbouloux, E, Mosnier, J-F, Bataille, F-R, Campone, M
Udgivet 2008

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

af Heudel, P-E, Fabbro, M, Roemer-Becuwe, C, Kaminsky, M C, Arnaud, A, Joly, F, Roche-Forestier, S, Meunier, J, Foa, C, You, B, Priou, F, Tazi, Y, Floquet, A, Selle, F, Berton-Rigaud, D, Lesoin, A, Kalbacher, E, Lortholary, A, Favier, L, Treilleux, I, Ray-Coquard, I
Udgivet i Br J Cancer (2017)

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer

af Poveda, A., del Campo, J. M., Ray-Coquard, I., Alexandre, J., Provansal, M., Guerra Alía, E. M., Casado, A., Gonzalez-Martin, A., Fernández, C., Rodriguez, I., Soto, A., Kahatt, C., Fernández Teruel, C., Galmarini, C. M., Pérez de la Haza, A., Bohan, P., Berton-Rigaud, D.
Udgivet i Ann Oncol (2017)